Equites Radar

ILMN · Illumina, Inc.

Diagnostics & ResearchUnited StatesAnalyst view: Buy

$189.47

+1.85% last session

End-of-day data · updated 2026-07-29

Bullish4 bullish · 1 bearish technical signals
Consensus: Buy (2.35 from 19 analysts)
To mean target: -8.9%

Market cap

$29B

Enterprise value

$31B

Trailing P/E

35.2

Forward P/E

32.5

Dividend yield

Beta

1.47

Avg volume

2M

Employees

9K

2D change

1.85%

5D change

10D change

3.39%

30D change

6.56%

60D change

18.42%

MTD change

4.94%

YTD change

47.13%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.35
Covering analysts19
Mean price target$172.53
Low price target$95.00
Upside to mean target-8.9%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)59.2
50-day MA$170.82
200-day MA$137.61
Price vs 50-day MA+13.0%
Price vs 200-day MA+40.2%
MACD histogram-0.89
Volume vs 3-month avg1.1×
52w low $91.0052w high $196.86

Analyst sentiment over time — ILMN

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-17

Latest call per bank · past 12 months

Barclays

Underweight

$145

-23.5% vs price
▲ raised from $122Maintains · 2026-06-24

JP Morgan

Overweight

$185

-2.4% vs price
▲ raised from $125Upgrade · 2026-06-10

Citigroup

Sell

$95.00

-49.9% vs price
▲ raised from $80.00Maintains · 2026-05-04

UBS

Neutral

$120

-36.7% vs price
▲ raised from $110Maintains · 2025-10-31

Morgan Stanley

Equal-Weight

$105

-44.6% vs price
▲ raised from $100Maintains · 2025-08-04

RBC Capital

Outperform

$126

-33.5% vs price
▲ raised from $118Maintains · 2025-08-01

Recent rating actions

DateFirmActionRatingPrice target
2026-07-17Leerink PartnersMaintainsOutperform$175 $210
2026-07-14Canaccord GenuityMaintainsHold$140 $190
2026-07-06Evercore ISI GroupMaintainsOutperform$155 $200
2026-07-01Piper SandlerMaintainsOverweight$170 $200
2026-06-29GuggenheimMaintainsBuy$180 $200
2026-06-24BarclaysMaintainsUnderweight$122 $145
2026-06-10JP MorganUpgradeNeutralOverweight$125 $185
2026-06-01GuggenheimMaintainsBuy$170 $180

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 59 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 13.0% above the 50-day MA ($170.82).
  • Price vs 200-day MA: Trading 40.2% above the 200-day MA ($137.61).
  • MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • MACD (12,26,9): MACD histogram is negative (-0.89) — short-term momentum is fading.
  • 52-week range: Price is within 5% of the 52-week high ($196.86).

ILMN Price Chart

Loading chart for ILMN

Fundamentals

Revenue (TTM)$4.0B
EBITDA$1.0B
Free cash flow$1.0B
Operating cash flow$1.0B
Book value / share$17.60
Net debt / EBITDA1.2
WACC13.0%
Revenue growth5.00%
Earnings growth6.00%

About Illumina, Inc.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

More in Diagnostics & Research

Screen ILMN against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.